Zinc finger nuclease knockout of CCR5 in hematopoetic stem cells as an anti-HIV gene therapy

2009 2009

Other formats: Order a copy

Abstract (summary)

CCR5 is the major co-receptor for HIV-1 entry and an important target for drug development. The recent finding that hematopoietic stem cell [1] transplantation from a CCR5-negative donor to an HIV-infected patient produces long-term virus control in the absence of antiretroviral drugs suggests the potential of stem cell and gene therapies targeting CCR5. To this end, we are developing a protocol to knock-out CCR5 in a patient's own HSC using CCR5-targeted zinc finger nucleases (ZFNs).

ZFNs are sequence specific proteins that generate a double-stranded break in DNA, which is converted into a gene-disrupting lesion by host repair processes. We have optimized the delivery and function of ZFNs targeting CCR5 in human CD34-positive HSC, achieving up to 27% disruption of CCR5 alleles. We confirmed that ZFN-treated HSC remain fully functional by transplanting a mouse model of human hematopoiesis, the NOD/SCID/IL2γcnull (NSG) mouse, where the modified HSC retained the ability to differentiate into multiple hematopoietic lineages.

Humanized NSG mice are additionally capable of supporting HIV-1 infection. Following challenge with an R5-tropic virus, control animals demonstrated altered CD4:CD8 ratios, profound loss of human cells in the thymus and GALT, and high viral loads in multiple tissues sampled. In contrast, ZFN-treated animals had significantly lower acute viral loads and very low levels of virus in tissues by 10-12 weeks post-infection. At this stage the numbers of human cells in tissues that are targets for HIV-1 infection had normalized, including the GALT and thymus. FACS and PCR analysis revealed a rapid and dramatic selection for CCR5-negative cells in these populations. These findings demonstrate that ZFN-treated HSC can generate HIV-resistant cells in vivo that rapidly replace cells depleted by HIV-1 infection, and importantly, preserve GALT populations. Transient ZFN treatment resulting in permanent disruption of CCR5 in autologous HSC could therefore represent a viable clinical approach for HIV-infected patients.

Indexing (details)

0720: Virology
Identifier / keyword
Biological sciences; Gene therapy; Hematopoetic stem cells; Zinc finger nucleases
Zinc finger nuclease knockout of CCR5 in hematopoetic stem cells as an anti-HIV gene therapy
Holt, Nathalia
Number of pages
Publication year
Degree date
School code
DAI-B 70/07, Dissertation Abstracts International
Place of publication
Ann Arbor
Country of publication
United States
Garry, Robbert F.
Committee member
Cannon, Paula M.; Morris, Cindy; Voss, Thomas
Tulane University
Biomedical Sciences
University location
United States -- Louisiana
Source type
Dissertations & Theses
Document type
Dissertation/thesis number
ProQuest document ID
Database copyright ProQuest LLC; ProQuest does not claim copyright in the individual underlying works.
Document URL
Access the complete full text

You can get the full text of this document if it is part of your institution's ProQuest subscription.

Try one of the following:

  • Connect to ProQuest through your library network and search for the document from there.
  • Request the document from your library.
  • Go to the ProQuest login page and enter a ProQuest or My Research username / password.